Nadia Caccamo, Serena Meraviglia, Giuseppe Cicero, Gaspare Gulotta, Francesco Moschella, Adriana Cordova, Eliana Gulotta, Alfredo Salerno and Francesco Dieli Pages 1147 - 1153 ( 7 )
Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.
Human γ δ T cells,tumors,phosphoantigens,bisphosphonates,immunotherapy
, , , , , , , , Dipartimento di Biopatologia e Metodologie Biomediche, Universita di Palermo, Corso Tukory 211,Palermo 90134 Italy.